ABSTRACT
We set out to determine the efficacy of indisetron hydrochloride for the management of chemotherapy-induced nausea and vomiting including carboplatin for lung cancer. Indisetron hydrochloride was given orally to 32 patients (indisetron group), and intravenous 5-HT3 receptor antagonists were given to 24 patients (control group). The number of patients with nausea or vomiting occurring within 24 hours and 24 to 72 hours after chemotherapy was measured. The complete inhibition of the vomiting within 24 hours after chemotherapy was 100% in the indisetron group and 95.8% in the control group. Twenty-four to 72 hours after chemotherapy, the complete inhibition of vomiting rate was 97.1% and 95.8%, respectively. In addition, the complete inhibition of nausea rate within 24 hours after chemotherapy was 87.5% in the indisetron group and that was 95.8% in the control group. The complete inhibition of nausea rate 24 to 72 hours after chemotherapy was 56.3% and 70.8%, respectively. No serious adverse events were observed. The comparison of the efficacy between the indisetron group and control groups did not reach statistical significance (p> 0.05). These findings suggest that prophylactic administration of indisetron hydrochloride is useful for the inhibition of acute and delayed nausea and vomiting caused by chemotherapy in lung cancer patients.
Subject(s)
Antiemetics/therapeutic use , Antineoplastic Agents/adverse effects , Bridged-Ring Compounds/therapeutic use , Lung Neoplasms/drug therapy , Nausea/prevention & control , Pyrazoles/therapeutic use , Vomiting/prevention & control , Adult , Aged , Aged, 80 and over , Antiemetics/administration & dosage , Bridged-Ring Compounds/administration & dosage , Carboplatin/adverse effects , Female , Humans , Male , Middle Aged , Nausea/chemically induced , Pyrazoles/administration & dosage , Retrospective Studies , Serotonin Antagonists/therapeutic use , Vomiting/chemically inducedABSTRACT
The patient was a 64-year-old woman who had undergone partial enterectomy for a small intestinal tumor in August 2005, and gastrointestinal stromal tumor (GIST) was diagnosed. Administration of imanitib mesylate was initiated as postoperative chemotherapy in November 2005. In February 2006, a slight ground-glass opacity was noted in the right lower lobe on chest CT. In April, cough and dyspnea appeared, and non-segmental reticular ground-glass opacity was noted in bilateral lung fields. Drug-induced pneumonia associated with imatinib mesylate was suspected based on the clinical course, and administration of imatinib mesylate was discontinued. Oral administration of 30mg prednisolone was initiated, and the symptoms and shadows on X-ray films improved. The steroid dose was gradually reduced, and recovery of the patient was smooth. Imatinib mesylate is anticipated to be a good potential therapeutic drug for interstitial pneumonia because it blocks PDGF receptors. However, the risk of imatinib-induced interstitial pneumonia should be noticed.
